C
Chandan Kanta Das
Researcher at Indian Institute of Technology Kharagpur
Publications - 16
Citations - 753
Chandan Kanta Das is an academic researcher from Indian Institute of Technology Kharagpur. The author has contributed to research in topics: Cancer & Autophagy. The author has an hindex of 11, co-authored 16 publications receiving 418 citations. Previous affiliations of Chandan Kanta Das include National Institute of Technology, Rourkela & Goethe University Frankfurt.
Papers
More filters
Journal ArticleDOI
Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers.
Chandan Kanta Das,Bikash Chandra Jena,Indranil Banerjee,Subhayan Das,Aditya Parekh,Sujit K. Bhutia,Mahitosh Mandal +6 more
TL;DR: The current status of exosome as a delivery vehicle for therapeutics and the challenges that need to be overcome are covered, and the future perspectives of this exciting field of research are discussed to transform it from bench to clinical reality.
Journal ArticleDOI
Pro-survival autophagy and cancer cell resistance to therapy
TL;DR: An up-to-date overview on the current knowledge of the role of pro-survival autophagy in cancer therapy at the preclinical and clinical stages is provided and the molecular mechanisms of Autophagy regulation in response to therapy-related stress conditions are delineated.
Journal ArticleDOI
Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer.
TL;DR: This study revealed that LDHA; one of the key molecules of glycolysis in association with Beclin-1 induced pro-survival autophagy in tamoxifen-resistant breast cancer.
Journal ArticleDOI
BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells
Chandan Kanta Das,Benedikt Linder,Florian Bonn,Florian Rothweiler,Ivan Dikic,Martin Michaelis,Jindrich Cinatl,Mahitosh Mandal,Donat Kögel +8 more
TL;DR: Genetic and pharmacological interference with BAG3 is capable to resensitize TNBC cells to treatment, underscoring its relevance for cell death resistance and as a target to overcome therapy resistance of breast cancer.
Journal ArticleDOI
Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy
Rashmi Bharti,Goutam Dey,Indranil Banerjee,Kaushik Kumar Dey,Sheetal Parida,B. N. Prashanth Kumar,Chandan Kanta Das,Ipsita Pal,Manabendra Mukherjee,Mridula Misra,Anjan K. Pradhan,Luni Emdad,Swadesh K. Das,Paul B. Fisher,Mahitosh Mandal +14 more
TL;DR: SST-DNL provides a novel strategy with better efficacy for breast cancer therapy and effectively inhibited the oncogenic IL-6/IL-6R/STAT3/MAPK/Akt signalling pathways as compared to DN or DNL in cancer cells.